Login to Your Account



ODAC Proves a Harsh Critic of Amgen's Xgeva in CRPC

By Mari Serebrov
Washington Editor

Thursday, February 9, 2012

"Show me the benefit" was the mantra Wednesday when an FDA advisory committee critiqued the ability of Amgen Inc.'s Xgeva to prolong the time until bone metastasis in men with castration-resistant prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription